share_log

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Akari Therapeutics公佈2024年第一季度財務業績和近期亮點
Akari Therapeutics ·  05/16 12:00

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024

與Peak Bio簽訂了最終合併協議;預計將於2024年第三季度完成

Samir R. Patel, M.D. Appointed Interim CEO

醫學博士薩米爾·帕特爾被任命爲臨時首席執行官

Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy

Peak Bio的ADC癌症治療平台技術和Akari的Pas-Nomacopan優先考慮地理萎縮的計劃

Implementation of Restructuring Plan to Reduce Operating Costs

實施重組計劃以降低運營成本

Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes

現有投資者支持公司發行100萬美元的無抵押可轉換票據

BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter ended March 31, 2024 as well as recent company highlights.

波士頓和倫敦,2024年5月16日(GLOBE NEWSWIRE)——開發自身免疫和炎症性疾病先進療法的後期生物技術公司Akari Therapeutics, Plc(納斯達克股票代碼:AKTX)公佈了截至2024年3月31日的第一季度財務業績以及最近的公司亮點。

"My first few weeks as Interim CEO of Akari have been filled with non-stop activity and optimism," said Samir R. Patel, MD, Akari Interim President and CEO. "We continue to work towards completion of the merger with Peak Bio, advance PAS-nomacopan in geographic atrophy, and explore value creation through business opportunities with nomacopan, a phase 3 ready compound. In addition, we continue to be incredibly optimistic about the potential opportunities afforded by Peak's ADC platform technology."

Akari臨時總裁兼首席執行官總經理薩米爾·帕特爾說:“我擔任Akari臨時首席執行官的前幾周充滿了不間斷的活動和樂觀情緒。”“我們將繼續努力完成與Peak Bio的合併,推進Pas-Nomacopan的地理萎縮,並通過Nomacopan(一種三期就緒化合物)的商機探索價值創造。此外,我們仍然對Peak的ADC平台技術所帶來的潛在機會持非常樂觀的態度。”

Recent Company Highlights

最近的公司亮點

  • Entered into a definitive agreement with Peak Bio Inc. (Peak Bio) to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. The merger is expected to close in the third quarter of 2024.
  • Announced portfolio prioritization plan for combined go-forward company which will focus on Peak's antibody drug conjugate (ADC) platform technology and Akari's PAS-nomacopan Geographic Atrophy (GA) program. As a result of this prioritization, the Company's HSCT-TMA program was suspended.
  • Announced key leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO, following the departure of Rachelle Jacques.
  • Commenced implementation of a reduction-in-force of approximately 67% of the Company's total workforce as part of an operational restructuring plan, which included the elimination of certain senior management positions, to reduce operating costs while supporting the Company's long-term strategic plan.
  • In May 2024, issued unsecured convertible, short-term promissory notes to Samir R. Patel, M.D, the Company's President and Chief Executive Officer, and Ray Prudo, M.D., the Company's Chairman of the Board, each in the amount of $500,000 to provide operating capital.
  • 與匹克生物公司(Peak Bio)簽訂了最終協議,在全股交易中進行平等合併。合併後的實體將以Akari Therapeutics, Plc的名義運營,預計該公司將繼續以AKTX的名義在納斯達克資本市場上市和交易。合併預計將於2024年第三季度完成。
  • 宣佈了合併後公司的投資組合優先排序計劃,該公司將專注於Peak的抗體藥物偶聯物(ADC)平台技術和Akari的PAS-Nomacopan地理萎縮(GA)計劃。由於這種優先順序,該公司的HSCT-TMA計劃被暫停。
  • 宣佈了關鍵的領導層變動,包括在雷切爾·雅克離職後,任命經驗豐富的生命科學企業家薩米爾·帕特爾醫學博士爲臨時首席執行官。
  • 作爲運營重組計劃的一部分,開始實施對公司總員工約67%的裁員,該計劃包括取消某些高級管理職位,以降低運營成本,同時支持公司的長期戰略計劃。
  • 2024年5月,向公司總裁兼首席執行官薩米爾·帕特爾醫學博士和公司董事會主席雷·普魯多醫學博士發行了金額爲50萬美元的無抵押可轉換短期本票,以提供運營資本。

First Quarter 2024 Financial Results

2024 年第一季度財務業績

As of March 31, 2024, the Company had cash of approximately $1.3 million.

截至2024年3月31日,該公司的現金約爲130萬美元。

Research and development expenses were approximately $2.3 million for the three months ended March 31, 2024, as compared to approximately $1.7 million for the same period in 2023.

截至2024年3月31日的三個月,研發費用約爲230萬美元,而2023年同期的研發費用約爲170萬美元。

General and administrative expenses were approximately $3.7 million for the three months ended March 31, 2024, as compared to approximately $2.9 million for the same period in 2023.

截至2024年3月31日的三個月,一般和管理費用約爲370萬美元,而2023年同期約爲290萬美元。

Total other income, net was approximately $0.4 million for the three months ended March 31, 2024, as compared to approximately $5.6 million for the same period in 2023, of which $0.6 million and $5.6 million was the result of net non-cash gains related to the company's liability-classified warrants issued in connection with the company's September 2022 private placement transaction.

截至2024年3月31日的三個月,其他收入淨額總額約爲40萬美元,而2023年同期約爲560萬美元,其中60萬美元和560萬美元是與公司2022年9月私募交易相關的負債分類認股權證相關的淨非現金收益的結果。

Net loss was approximately $5.6 million for the three months ended March 31, 2024, as compared to net income of approximately $1.0 million for the same period in 2023. Excluding the non-cash gains of approximately $0.6 million and $5.6 million for the three months ended March 31, 2024 and 2023, respectively, related to the company's liability-classified warrants, net loss was $6.2 million and $4.6 million, respectively.

截至2024年3月31日的三個月,淨虧損約爲560萬美元,而2023年同期的淨收入約爲100萬美元。不包括截至2024年3月31日和2023年3月31日的三個月中分別與公司負債分類認股權證相關的約60萬美元和560萬美元的非現金收益,淨虧損分別爲620萬美元和460萬美元。

Readers are referred to, and encouraged to read in its entirety, the company's Quarterly Report on Form 10-Q for the three months ended March 31, 2024, as filed with the Securities and Exchange Commission on March 15, 2024, which includes further detail on the Company's business plans, operations, financial condition, and results of operations.

請讀者參閱並鼓勵讀者完整閱讀公司於2024年3月15日向美國證券交易委員會提交的截至2024年3月31日的三個月的10-Q表季度報告,其中包括有關公司業務計劃、運營、財務狀況和經營業績的更多細節。

About the Merger

關於合併

On March 5, 2024, Akari and Peak Bio announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX, under the Chairmanship of Hoyoung Huh, MD, PhD. Under the terms of the agreement, Peak stockholders will receive a number of Akari ordinary shares (represented by American Depositary Shares) for each share of Peak stock they own, as determined on the basis of the exchange ratio described in the agreement. The exchange is expected to result in implied equity ownership in the combined company of approximately 50% for Akari shareholders and approximately 50% for Peak stockholders on a fully diluted basis, subject to adjustment under certain circumstances, including based on each party's relative level of net cash at the closing of the proposed transaction. The transaction is expected to close by the third quarter of this year subject to the satisfaction of customary closing conditions, including approval by the shareholders of both companies.

2024年3月5日,Akari和Peak Bio宣佈了一項最終協議,將在全股交易中平等合併。合併後的實體將以Akari Therapeutics, Plc的名義運營,預計該公司將繼續以AKTX的名義在納斯達克資本市場上市和交易,由醫學博士Hoyoung Huh擔任主席。根據協議條款,Peak股東每持有Peak股票將獲得一定數量的Akari普通股(由美國存托股代表),具體取決於協議中描述的兌換率。在全面攤薄的基礎上,該交易所預計將使合併後的公司的隱含股權所有權爲Akari股東約50%,Peak股東的隱含股權所有權約爲50%,在某些情況下會進行調整,包括根據擬議交易結束時各方的相對淨現金水平進行調整。該交易預計將於今年第三季度完成,但須滿足慣例成交條件,包括兩家公司股東的批准。

About Akari Therapeutics

關於阿卡里療法

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Akari Therapeutics, plc(納斯達克股票代碼:AKTX)是一家生物技術公司,爲自身免疫和炎症性疾病開發先進療法。Akari的主要資產,研究型nomacopan,是一種具有補體C5激活和白三烯B4(LTB4)活性的雙特異性重組抑制劑。該公司正在對地理萎縮(GA)中的長效Pas-Nomacopan進行臨床前研究。有關 Akari 的更多信息,請訪問 akaritx.com。

Cautionary Note Regarding Forward-Looking Statements

關於前瞻性陳述的警示說明

This communication includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), about the proposed transaction between Peak Bio and Akari and the operations of the combined company that involve risks and uncertainties relating to future events and the future performance of Akari and Peak Bio. Actual events or results may differ materially from these forward-looking statements. Words such as "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "future," "opportunity" "will likely result," "target," variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the business combination and related matters, including, but not limited to, satisfaction of closing conditions to the proposed transaction, prospective performance and opportunities with respect to Akari or Peak Bio, post-closing operations and the outlook for the companies' businesses; Akari's, Peak Bio's or the combined company's targets, plans, objectives or goals for future operations, including those related to Akari's and Peak Bio's product candidates, research and development, product candidate introductions and product candidate approvals as well as cooperation in relation thereto; projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; future economic performance, future actions and outcome of contingencies such as legal proceedings; and the assumptions underlying or relating to such statements.

本通信包括經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》(“交易法”)第21E條所指的明示或暗示的前瞻性陳述,內容涉及Peak Bio與Akari之間的擬議交易以及合併後公司的業務,這些交易涉及與Akari和Peak Bio未來業績相關的風險和不確定性。實際事件或結果可能與這些前瞻性陳述存在重大差異。諸如 “將”、“可以”、“將”、“應該”、“期望”、“計劃”、“預期”、“打算”、“相信”、“估計”、“預測”、“項目”、“潛力”、“繼續”、“將來”、“機會” “可能的結果”、“目標” 等詞語以及這些詞語的類似表述或否定詞旨在識別此類詞語前瞻性陳述,儘管並非所有前瞻性陳述都包含這些識別詞。此類前瞻性陳述的示例包括但不限於有關以下方面的明示或暗示陳述:業務合併及相關事項,包括但不限於對擬議交易成交條件的滿足、Akari或Peak Bio的預期業績和機會、收盤後的業務和公司業務前景;Akari、Peak Bio或合併後的公司未來運營目標、計劃、目標或目標,包括與Akari相關的目標、計劃、目標或目標 Ari's 和 Peak Bio 的產品候選人、研發、候選產品介紹和候選產品的批准以及與之相關的合作;收入、成本、收入(或虧損)、每股收益、資本支出、股息、資本結構、淨財務狀況和其他財務指標的預測或目標;未來的經濟表現、未來行動和法律訴訟等突發事件的結果;以及此類陳述所依據或與之相關的假設。

These statements are based on Akari's current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing for completion of the proposed transaction; uncertainties as to Peak Bio's and/or Akari's ability to obtain the approval of Akari's shareholders or Peak Bio's stockholders required to consummate the proposed transaction; the possibility that competing offers will be made by third parties; the occurrence of events that may give rise to a right of one or both of Akari and Peak Bio to terminate the merger agreement; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived on a timely basis or at all, including the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of consents or regulatory approvals or actions, if any; the possibility that the proposed transaction may not be completed in the time frame expected, or at all; the risk that Akari may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the effects of the proposed transaction on relationships with Akari's or Peak Bio's employees, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; significant or unexpected costs, charges or expenses resulting from the proposed transaction; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business after the consummation of the proposed transaction; potential negative effects related to this announcement or the consummation of the proposed transaction on the market price of Akari's American Depositary Shares and Akari's operating or financial results; uncertainties as to the long-term value of Akari's American Depositary Shares (and the ordinary shares represented thereby), including the dilution caused by Akari's issuance of additional American Depositary Shares (and the ordinary shares represented thereby) in connection with the proposed transaction; unknown liabilities related to Akari or Peak Bio; the nature, cost and outcome of any litigation and other legal proceedings involving Akari, Peak Bio or their respective directors, including any legal proceedings related to the proposed transaction; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of Akari's programs or product candidates; risks related to any loss of Akari's patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for Akari product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by Akari, or its collaborators or licensees; the extent to which the results from the research and development programs conducted by Akari, Peak Bio, and/or their respective collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of Akari's product candidates, and the impact of studies (whether conducted by Akari or others and whether mandated or voluntary) on any of the foregoing; unexpected breaches or terminations with respect to Akari's material contracts or arrangements; risks related to competition for Akari's product candidates; Akari's ability to successfully develop or commercialize Akari's product candidates; Akari's, or its collaborators' abilities to continue to conduct current and future developmental, preclinical and clinical programs; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of Akari's product candidates; unexpected increase in costs and expenses with respect to the potential transaction or Akari's business or operations; and risks and uncertainties related to epidemics, pandemics or other public health crises and their impact on Akari's business, operations, supply chain, patient enrollment and retention, preclinical and clinical trials, strategy, goals and anticipated milestones. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the proposed transaction or any other transaction described above will in fact be consummated in the manner described or at all. A more complete description of these and other material risks can be found in Akari's filings with the U.S. Securities and Exchange Commission (the "SEC"), including Akari's Annual Report on 10-K, for the year ended December 31, 2023, subsequent periodic reports, and other documents that may be filed from time to time with the SEC. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the joint proxy statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction, which joint proxy statement/prospectus will be mailed or otherwise disseminated to Akari's shareholders when it becomes available.

這些陳述基於Akari當前的計劃、估計和預測。就其本質而言,前瞻性陳述涉及固有的風險和不確定性,包括一般和具體的。許多重要因素,包括本通報中描述的因素,可能導致實際業績與任何前瞻性陳述中設想的結果存在重大差異。可能影響未來業績並可能導致這些前瞻性陳述不準確的因素包括但不限於:擬議交易完成時間的不確定性;完成擬議交易所需的Peak Bio和/或Akari獲得Akari股東或Peak Bio股東批准的能力的不確定性;第三方提出競爭要約的可能性;可能導致Akari一方或兩方權利的事件的發生 Ari 和 Peak Bio 將終止合併協議;可能無法及時或根本不滿足或放棄擬議交易的各種成交條件,包括政府實體可能在需要時禁止、推遲或拒絕批准擬議交易(或僅在不利條件或限制條件下給予批准);難以預測同意、監管部門批准或行動(如果有)的時間或結果;擬議的交易可能無法按時完成設定預期或根本無法實現擬議交易的預期收益的風險;擬議交易對與Akari's或Peak Bio員工、業務或合作伙伴或政府實體關係的影響;保留和僱用關鍵人員的能力;因宣佈或完成擬議交易而產生的潛在不良反應或業務關係變化;由此產生的重大或意外成本、費用或支出來自擬議交易;擬議交易完成後不可預見的負債、未來資本支出、收入、成本、支出、收益、協同效應、經濟表現、債務、財務狀況和虧損對未來前景、管理、擴張和增長的業務和管理戰略的潛在影響;與本公告或擬議交易的完成相關的潛在負面影響,對Akari美國存托股份和Akari市價的潛在負面影響的經營或財務業績;Akari美國存托股份(及由此代表的普通股)長期價值的不確定性,包括Akari發行與擬議交易相關的額外美國存托股(及由此代表的普通股)造成的稀釋;與Akari或Peak Bio相關的未知負債;涉及Akari、Peak Bio或其各自董事的任何訴訟和其他法律訴訟的性質、成本和結果,包括任何與之相關的法律訴訟擬議交易;與全球和當地政治和經濟狀況相關的風險,包括利率和貨幣匯率波動;與Akari項目或候選產品的研發相關的潛在延遲或失敗;與Akari專利或其他知識產權損失相關的風險;Akari候選產品原材料或生產供應鏈的任何中斷,候選產品的性質、時機、成本和可能的成功和治療應用由Akari或其合作者或被許可人開發;Akari、Peak Bio和/或其各自合作者或被許可方開展的研發計劃的結果在多大程度上可以在其他研究中複製和/或導致候選產品進入臨床試驗、治療應用或監管機構批准的階段;Akari候選產品的使用、市場接受度和商業成功的不確定性,以及研究(無論是由Akari還是由Akari進行的)的影響其他(無論是授權的還是自願的)關於上述任何內容;與Akari重大合同或安排有關的意外違規或終止;與Akari候選產品競爭相關的風險;Akari成功開發或商業化Akari候選產品的能力;Akari或其合作者繼續開展當前和未來開發、臨床前和臨床項目的能力;法律訴訟和調查的潛在風險;與政府法律變更及其相關解釋相關的風險,包括償還費用,對Akari任何候選產品的測試、批准、製造、開發或商業化的知識產權保護和監管控制;與潛在交易或Akari業務或運營有關的成本和支出的意外增加;與流行病、流行病或其他公共衛生危機相關的風險和不確定性及其對Akari業務、運營、供應鏈、患者招募和留用、臨床前和臨床試驗、戰略、目標和預期里程碑的影響。儘管此處列出的上述因素清單被認爲具有代表性,但不應將任何清單視爲對所有潛在風險和不確定性的完整陳述。無法保證擬議的交易或上述任何其他交易實際上會以上述方式完成,或者根本無法保證。對這些風險和其他重大風險的更完整描述可以在Akari向美國證券交易委員會(“SEC”)提交的文件中找到,包括Akari截至2023年12月31日的年度10-K年度報告、隨後的定期報告以及可能不時向美國證券交易委員會提交的其他文件。這些風險以及與擬議交易相關的其他風險將在聯合委託書/招股說明書中進行更全面的討論,該委託書/招股說明書將包含在與擬議交易相關的S-4表格註冊聲明中,聯合委託書/招股說明書發佈後將郵寄或以其他方式分發給Akari的股東。

Any forward-looking statements speak only as of the date of this communication and are made based on the current beliefs and judgments of Akari's management, and the reader is cautioned not to rely on any forward-looking statements made by Akari. Unless required by law, Akari is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.

任何前瞻性陳述僅代表截至本通報之日,並基於Akari管理層當前的信念和判斷作出,並提醒讀者不要依賴Akari的任何前瞻性陳述。除非法律要求,否則在本文件發佈後,Akari沒有義務也沒有義務更新或修改任何前瞻性陳述,包括但不限於任何財務預測或指導,無論是由於新信息、未來事件還是其他原因。

No Offer or Solicitation

不得提出要約或邀請

This communication is not intended to and shall not constitute an offer to subscribe for, buy or sell or the solicitation of an offer to subscribe for, buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of, or offer to sell or buy, securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is for informational purposes only. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

本通信無意也不構成認購、買入或賣出要約,或徵求任何證券的認購、買入或賣出要約,或徵求任何投票或批准,在根據任何此類司法管轄區的證券法進行註冊或資格認定之前,此類要約、招攬或出售爲非法的任何司法管轄區,也不得進行任何證券的出售或要約出售或買入證券。此通信僅供參考。除非通過符合經修訂的1933年《美國證券法》第10條要求的招股說明書以及根據適用法律以其他方式發行證券。

Additional Information and Where to Find It

其他信息以及在哪裏可以找到

In connection with the proposed transaction, Akari and Peak Bio expect to file with the SEC a Registration Statement on Form S-4. The Registration Statement on Form S-4 will include a prospectus of Akari and a joint proxy statement of Akari and Peak Bio, and each party may also file other documents regarding the proposed transaction with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE REGISTRATION STATEMENT ON FORM S-4, JOINT PROXY STATEMENT/ PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN, IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.

關於擬議的交易,Akari和Peak Bio預計將向美國證券交易委員會提交一份關於S-4表格的註冊聲明。S-4表格上的註冊聲明將包括Akari的招股說明書以及Akari和Peak Bio的聯合委託聲明,各方還可以向美國證券交易委員會提交有關擬議交易的其他文件。我們敦促投資者和證券持有人仔細閱讀S-4表格上的註冊聲明、聯合委託書/招股說明書以及向美國證券交易委員會提交或將要提交的其他相關文件,以及任何修正案或補充文件以及其中以引用方式納入的任何文件,如果這些文件包含或將包含有關擬議交易、相關事項和擬議交易各方的重要信息,則應全部閱讀這些文件。

You may obtain a free copy of the Registration Statement on Form S-4, joint proxy statement/prospectus and other relevant documents (if and when they become available) that are or will be filed with the SEC for free at the SEC's website at www.sec.gov. Copies of the documents filed with the SEC by Akari will be available free of charge on Akari's website at http://investor.akaritx.com/ or by contacting Akari's Investor Relations Department at http://investor.akaritx.com/investor-resources/contact-us. Copies of the documents filed with the SEC by Peak Bio will be available free of charge on Peak Bio's website at https://peak-bio.com/investors or by contacting Peak Bio's Investor Relations Department at https://peak-bio.com/contact.

您可以在美國證券交易委員會網站www.sec.gov上免費獲得S-4表格註冊聲明、聯合委託書/招股說明書以及其他相關文件(如果可用)的副本,這些文件已經或將要向美國證券交易委員會免費提交。Akari向美國證券交易委員會提交的文件的副本將在Akari的網站 http://investor.akaritx.com/ 上免費提供,也可以致電http://investor.akaritx.com/investor-resources/contact-us 與Akari的投資者關係部聯繫。Peak Bio向美國證券交易委員會提交的文件的副本將在Peak Bio的網站 https://peak-bio.com/investors 上免費提供,也可以致電https://peak-bio.com/contact 與Peak Bio的投資者關係部聯繫。

Participants in the Solicitation

招標參與者

Akari, Peak Bio and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of Akari, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Akari's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 29, 2024, subsequent quarterly and current reports on Form 10-Q and -K, respectively, and other documents that may be filed from time to time with the SEC. Information about the directors and executive officers of Peak Bio, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Peak Bio's proxy statement for its 2022 Special Meeting of Stockholders, which was filed with the SEC on October 19, 2022, the Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on June 29, 2023, subsequent quarterly and current reports on Form 10-Q and Form 8-K, respectively, and other documents that may be filed from time to time with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus included in the Registration Statement on Form S-4 and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available. Security holders, potential investors and other readers should read the joint proxy statement/prospectus, included in the Registration Statement on Form S-4 carefully when it becomes available before making any voting or investment decision. You may obtain free copies of these documents from Akari or Peak Bio using the sources indicated above.

Akari、Peak Bio及其各自的董事和執行官以及其他管理層成員和員工可能被視爲就擬議交易徵集代理人的參與者。Akari於2024年3月29日向美國證券交易委員會提交的截至2023年12月31日止年度的10-K表年度報告、隨後分別關於10-Q表和-K表的季度和當前報告,以及可能不時向美國證券交易委員會提交的其他文件中列出了有關Akari董事和執行官的信息,包括對他們通過證券持股或其他方式的直接或間接權益的描述。Peak Bio於2022年10月19日向美國證券交易委員會提交的2022年股東特別會議委託書、2023年6月29日向美國證券交易委員會提交的截至2022年12月31日止年度的10-K表年度報告、隨後在10-Q表和8-K表中提交的Peak Bio的2022年股東特別會議委託書中列出了有關其董事和執行官的信息,包括對他們的直接或間接權益的描述分別以及可能不時向美國證券交易委員會提交的其他文件。有關代理委託參與者的其他信息,以及對他們通過證券持股或其他方式產生的直接和間接利益的描述,將包含在S-4表格註冊聲明中包含的聯合委託書/招股說明書以及此類材料可用後向美國證券交易委員會提交的有關擬議交易的其他相關材料中。證券持有人、潛在投資者和其他讀者在做出任何投票或投資決定之前,應仔細閱讀S-4表格註冊聲明中包含的聯合委託書/招股說明書。您可以使用上述來源從Akari或Peak Bio免費獲得這些文件的副本。

For more information

欲了解更多信息

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com

投資者聯繫人:
邁克·莫耶
生命科學顧問
(617) 308-4306
mmoyer@lifesciadvisors.com

Akari Therapeutics Plc
Condensed Consolidated Statements of Operations and Comprehensive Loss (Income)
(Unaudited, in U.S. dollars)

Akari 治療有限公司
簡明合併運營報表和綜合虧損(收益)
(未經審計,以美元計)

Three Months Ended
March 31,
(in thousands, except per share amounts) 2024 2023
Operating expenses:
Research and development $ 2,279 $ 1,731
General and administrative 3,710 2,863
Loss from operations (5,989) (4,594)
Other income (expense):
Change in fair value of warrant liability 649 5,587
Other (expense) income, net (226) 8
Net (loss) income $ (5,566) $ 1,001
Net (loss) income per ordinary share — basic and diluted $ (0.00) $ 0.00
Weighted-average number of ordinary shares used in computing net (loss) income per share
— Basic 13,453,147,979 7,474,546,753
— Diluted 13,453,147,979 7,573,542,457
三個月已結束
3月31日
(以千計,每股金額除外) 2024 2023
運營費用:
研究和開發 $ 2,279 $ 1,731
一般和行政 3,710 2,863
運營損失 (5,989) (4,594)
其他收入(支出):
認股權證負債公允價值的變化 649 5,587
其他(支出)收入,淨額 (226) 8
淨(虧損)收入 $ (5,566) $ 1,001
每股普通股淨(虧損)收益——基本收益和攤薄後收益 $ (0.00) $ 0.00
用於計算每股淨(虧損)收益的普通股加權平均數
— 基本 13,453,147,979 7,474,546,753
— 稀釋 13,453,147,979 7,573,542,457

Akari Therapeutics Plc
Condensed Consolidated Balance Sheet Data
(Unaudited, in U.S. dollars)

Akari 治療有限公司
簡明的合併資產負債表數據
(未經審計,以美元計)

March 31, December 31,
($'s in thousands) 2024 2023
Cash $ 1,310 $ 3,845
Other assets 1,462 510
Total assets $ 2,772 $ 4,355
Total liabilities $ 6,325 $ 4,584
Total shareholders' deficit (3,553) (229)
Total liabilities and shareholders' deficit $ 2,772 $ 4,355
3月31日 十二月三十一日
(以千美元計) 2024 2023
現金 $ 1,310 $ 3,845
其他資產 1,462 510
總資產 $ 2,772 $ 4,355
負債總額 $ 6,325 $ 4,584
股東赤字總額 (3,553) (229)
負債總額和股東赤字 $ 2,772 $ 4,355

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論